US 12,257,242 B2
Inhibition of crystal growth of roflumilast
David W. Osborne, Fort Collins, CO (US)
Assigned to ARCUTIS Biotherapeutics, Inc., Westlake Village, CA (US)
Filed by ARCUTIS Biotherapeutics, Inc., Westlake Village, CA (US)
Filed on Sep. 12, 2023, as Appl. No. 18/465,446.
Application 15/676,356 is a division of application No. 15/616,409, filed on Jun. 7, 2017, granted, now 9,895,359, issued on Feb. 20, 2018.
Application 18/465,446 is a continuation of application No. 17/102,056, filed on Nov. 23, 2020, granted, now 11,793,796, issued on Oct. 24, 2023.
Application 17/102,056 is a continuation of application No. 16/136,804, filed on Sep. 20, 2018, granted, now 10,940,142, issued on Mar. 9, 2021.
Application 16/136,804 is a continuation of application No. 15/848,505, filed on Dec. 20, 2017, granted, now 10,105,354, issued on Oct. 23, 2018.
Application 15/848,505 is a continuation of application No. 15/676,356, filed on Aug. 14, 2017, granted, now 9,884,050, issued on Feb. 6, 2018.
Prior Publication US 2023/0414589 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/44 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/14 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); C09K 15/06 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/145 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); C09K 15/06 (2013.01)] 25 Claims
 
1. A topical pharmaceutical composition comprising roflumilast in an amount of 0.05%-1% w/w, hexylene glycol, and water, wherein the hexylene glycol is in an amount sufficient to inhibit crystal growth of roflumilast in the composition for at least six weeks of storage at 15° C.-26° C., wherein the composition is in the form of a cream or foam.